Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6465698

COCCOc1cc(OC)cc2c(C)nc(Nc3nc(O)c4cccc(OC)c4n3)nc12.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.39
PIK3CA P42336 1/20 0.36
CNR2 P34972 1/20 0.36
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
CREBBP Q92793 1/20 0.35
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6470467 0.91 ADORA2A (0.40) ADORA2AKMT2ASMN1; SMN2ALDH1A1MEN1
Trifluoroacetic Acid SCHEMBL6468655 0.88 FGFR1 (0.39) ADORA2AKMT2ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL6470553 0.86 GAA (0.42) KMT2ASMN1; SMN2ALDH1A1MEN1MAPK1
SCHEMBL6465702 0.86 ADORA2A (0.39) ADORA2APIK3CAKMT2ASMN1; SMN2ALDH1A1
Trifluoroacetic Acid SCHEMBL6470296 0.86 GAA (0.36) ADORA2AKMT2ASMN1; SMN2ALDH1A1PKM
Trifluoroacetic Acid SCHEMBL6470355 0.85 KMT2A (0.35) ADORA2AKMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL6469112 0.83 JUND (0.43) KMT2ASMN1; SMN2ALDH1A1PKMCREBBP
Trifluoroacetic Acid SCHEMBL6467382 0.82 ALDH1A1 (0.38) KMT2ASMN1; SMN2ALDH1A1MEN1TSHR
Trifluoroacetic Acid SCHEMBL6467456 0.82 KMT2A (0.36) ADORA2AKMT2ASMN1; SMN2ALDH1A1PKM
Trifluoroacetic Acid SCHEMBL6468039 0.81 PAX8 (0.40) ADORA2AKMT2ASMN1; SMN2ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB ADORA2A 4250/4885PIK3CA 1414/4885CNR2 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.